Amarin Corp Plc (AMRN) Posts Q1 Loss of 16c/Share; Updates on Ops
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Second-Half Vascepa Sales Growth Still in Focus for Amarin (AMRN); Aegis Maintains at 'Hold'
May 12, 2014 9:31 AM EDTAegis Capital maintains its Hold rating and $2 price target on Amarin Corp. (Nasdaq: AMRN) following Q1 results reported last week.
Analyst Ram Selvaraju Vascepa sales came in lighter than expected at $1.1 million, though R&D expenses of $11.7 million compared with the analysts... More
UPDATE: Citi Downgrades Amarin Corporation (AMRN) to Neutral
May 12, 2014 6:42 AM EDT(Updated - May 12, 2014 10:07 AM EDT)
Citi downgraded Amarin Corporation (NASDAQ: AMRN) from Buy to Neutral with a price target of $1.75. Analyst Jonathan Eckard thinks shares will trade range-bound near-term.
"We are downgrading AMRN to Neutral from Buy, finding it harder to see when Vascepa sales could turn a corner to drive support back to the stock. Dragging sales... More
